Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695003 | 0.87 | OPRM1 (0.48) | OPRM1OPRD1OPRK1MAPK1NPSR1 | |
| SCHEMBL3701085 | 0.82 | OPRM1 (0.47) | OPRM1OPRD1OPRK1MAPK1NPSR1 | |
| SCHEMBL3694831 | 0.82 | OPRM1 (0.69) | OPRM1OPRD1OPRK1PARP10PARP15 | |
| SCHEMBL4018970 | 0.81 | CARM1 (0.42) | OPRM1OPRD1OPRK1MAPK1NPSR1 | |
| SCHEMBL4014221 | 0.81 | MEN1 (0.36) | OPRM1OPRD1OPRK1PARP10PARP15 | |
| SCHEMBL3694628 | 0.80 | OPRK1 (0.49) | OPRM1OPRD1OPRK1PARP10MAPK1 | |
| SCHEMBL6205609 | 0.79 | OPRM1 (0.49) | OPRM1OPRD1OPRK1HTTCARM1 | |
| SCHEMBL4806912 | 0.77 | CACNA1G (0.40) | MAPK1NPSR1MAPTL3MBTL1MITF | |
| SCHEMBL13773057 | 0.76 | OPRM1 (0.69) | OPRM1OPRD1OPRK1P2RX3 | |
| SCHEMBL3700891 | 0.74 | OPRM1 (0.50) | OPRM1OPRD1OPRK1MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2208727-A1 | Diaryl ethers as opioid receptor antagonist | Eli Lilly & Company (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | OPRM1 1/4885OPRD1 2/4885OPRK1 4/4885 |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | OPRM1 1/4885OPRD1 2/4885OPRK1 4/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.